Clinical Cancer Research, Vol 4, Issue 2 399-405, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Quantitative differences in telomerase activity among malignant, premalignant, and benign ovarian lesions

S Kyo, M Takakura, M Tanaka, K Murakami, R Saitoh, H Hirano and M Inoue
Department of Obstetrics and Gynecology, School of Medicine, Kanazawa University, Japan. satoruky@med.kanazawa-u.ac.jp

Telomerase activation has been demonstrated in both cancers and some noncancerous lesions. However, few studies have determined levels of telomerase activity in these lesions. In the present study, using a recently developed stretch PCR assay, telomerase activity was quantitatively determined in a variety of ovarian lesions including 36 ovarian cancers, 5 ovarian low potential malignancy (LPM) lesions, 10 ovarian cysts, and 12 normal ovaries. Telomerase activity was normalized to control activity (100 units) in C33A cell line and given in relative units. Telomerase activity in ovarian cancer (51 +/- 7 units, mean +/- SE) was significantly higher than that in LPM lesions, ovarian cysts, and normal ovaries (7 +/- 3, 10 +/- 2, and 10 +/- 2 units, respectively; P < 0.001). Interestingly, all LPMs, ovarian cysts, and normal ovaries exhibited low telomerase activity less than 30 units, and no significant difference in level of telomerase activity was found among them. We also found a significant correlation between the level of telomerase activity and the clinical stage of ovarian cancer. Our quantitative telomerase assay thus clearly distinguished telomerase activity in ovarian cancers from that in LPM lesions and ovarian cysts. Significant levels of telomerase activation frequently occurred in cancer but rarely occurred in premalignant and benign lesions, suggesting that telomerase activation is a critical step in cancer development.

This article has been cited by other articles:

				J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al. A Genetically Defined Model for Human Ovarian Cancer Cancer Res., March 1, 2004; 64(5): 1655 - 1663. [Abstract] [Full Text] [PDF]

				F. Barbieri, M. Cagnoli, N. Ragni, G. Foglia, C. Bruzzo, F. Pedulla, and A. Alama Increased Cyclin D1 Expression Is Associated with Features of Malignancy and Disease Recurrence in Ovarian Tumors Clin. Cancer Res., July 1, 1999; 5(7): 1837 - 1842. [Abstract] [Full Text] [PDF]

				M. Tanaka, S. Kyo, M. Takakura, T. Kanaya, T. Sagawa, K. Yamashita, Y. Okada, E. Hiyama, and M. Inoue Expression of Telomerase Activity in Human Endometrium Is Localized to Epithelial Glandular Cells and Regulated in a Menstrual Phase-Dependent Manner Correlated with Cell Proliferation Am. J. Pathol., December 1, 1998; 153(6): 1985 - 1991. [Abstract] [Full Text] [PDF]